Clinical Research Directory
Browse clinical research sites, groups, and studies.
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Sponsor: China Medical University Hospital
Summary
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.
Official title: NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-10-12
Completion Date
2028-03
Last Updated
2025-02-19
Healthy Volunteers
No
Conditions
Interventions
NMDAE
Use of an NMDA enhancer for the treatment of CIAS
Placebo Cap
Use of placebo as a comparator
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan